CervoMed Inc. (CRVO)
| Market Cap | 38.10M -58.8% |
| Revenue (ttm) | 331,295 -95.7% |
| Net Income | -30.35M |
| EPS | -3.19 |
| Shares Out | 15.12M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,287 |
| Open | 2.500 |
| Previous Close | 2.510 |
| Day's Range | 2.470 - 2.530 |
| 52-Week Range | 2.130 - 10.480 |
| Beta | -4.31 |
| Analysts | Strong Buy |
| Price Target | 15.40 (+511.11%) |
| Earnings Date | Aug 10, 2026 |
About CRVO
CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. The company is developing neflamapimod, an orally administered small molecule drug that crosses the blood–brain barrier and inhibits the enzyme p38α. Neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health, and slow or prevent disease progression. Neflamapimod is currently in clinical development for the treatment of dementia with Lewy bodies, non-fluent variant... [Read more]
Financial Performance
In 2025, CervoMed's revenue was $4.01 million, a decrease of -58.86% compared to the previous year's $9.74 million. Losses were -$26.97 million, 65.5% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for CRVO stock is "Strong Buy." The 12-month stock price target is $15.4, which is an increase of 511.11% from the latest price.
News
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting
CervoMed to Participate in September Investor Conferences
BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), tod...
CervoMed price target lowered to $7 from $9 at Roth Capital
Roth Capital lowered the firm’s price target on CervoMed (CRVO) to $7 from $9 and keeps a Buy rating on the shares. The firm updated the company’s model post the…
CervoMed Transcript: Canaccord Genuity's 46th Annual Growth Conference
Significant clinical and regulatory progress was reported for a phase III-ready DLB drug, with new data supporting its targeted mechanism and clinical efficacy. Expansion into PPA and ALS indications is underway, with key biomarker and trial milestones expected later this year.
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Prioritizing strategic partnership to advance neflamapimod into Phase 3 for the treatment of dementia with Lewy bodies (DLB) Neflamapimod awarded Innovation Passport Designation under the United Kingd...
CervoMed price target lowered to $18 from $27 at Canaccord
Canaccord analyst Sumant Kulkarni lowered the firm’s price target on CervoMed (CRVO) to $18 from $27 and keeps a Buy rating on the shares. The firm said they continue to…
CervoMed Quarterly report: Q2 2026
CervoMed has published its Q2 2026 quarterly earnings report on August 7, 2026.
CervoMed Earnings release: Q2 2026
CervoMed released its Q2 2026 earnings on August 7, 2026, summarizing the period's financial results.
CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Innovation Passport award designed to support accelerated time to market and help expedite patient access to potentially transformative new investigational medicines
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
BOSTON, July 14, 2026 (GLOBE NEWSWIRE) -- CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
CervoMed completes enrollment in neflamapimod study
CervoMed (CRVO) announced that it has completed enrollment in the Phase 2a study of neflamapimod for the treatment of nfvPPA, a type of FTD. Interim biomarker data from the study…
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
Interim biomarker data accepted for presentation at the 19 th Clinical Trials on Alzheimer's Disease (CTAD) conference
CervoMed registers to sell 10.08M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 10.08M shares of common stock. The company is not selling any…
CervoMed Registration statement: Registration filing
CervoMed filed a registration statement on July 6, 2026, providing details about a securities offering with the SEC.
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
Latest findings on neflamapimod to be featured in presentations demonstrating its impact on dementia with Lewy bodies (DLB) disease progression, biomarkers of neurodegeneration, and basal forebrain at...
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
BOSTON, June 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed announces $10M registered direct offering priced at-the-market
CervoMed (CRVO) announced that it has entered into definitive agreements for the purchase and sale of 2,500,000 shares of common stock at a purchase price of $4.00 per share in…
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed receives notice of allowance from USPTO on neflamapimod
CervoMed (CRVO) announced that it has received a notice of allowance from the United States Patent and Trademark Office, USPTO, related to a new patent protecting the Company’s use of…
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference
Neflamapimod is advancing toward a pivotal phase III trial in DLB, supported by strong phase II data, regulatory alignment, and a recent financing that extends the cash runway into 2027. The company is prioritizing a strategic partnership to fund the trial and maximize value, with additional clinical catalysts expected in PPA and ALS.
CervoMed Slides: 7th Annual HCW Neuro Perspectives Hybrid Conference
CervoMed has posted slides in relation to its latest quarterly earnings report, which was published on June 15, 2026.
CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today an...
CervoMed announces $10.5M private placement
CervoMed (CRVO) announced that it has entered into a definitive securities purchase agreement for a private placement, from which the company anticipates upfront gross proceeds of approximately $10.5M...